Benzinga | Feb 10, 2021 06:54AM EST

Mizuho Downgrades Corvus Pharmaceuticals to Neutral, Lowers Price Target to $4

Mizuho analyst Mara Goldstein downgrades Corvus Pharmaceuticals (NASDAQ:CRVS) from Buy to Neutral and lowers the price target from $7 to $4.